Skip to content
TrialScanner

NCT02514382

Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1CompletedONCYCollaborator

Registry record

Lead sponsor
University of Southern California
Conditions
Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma
Primary completion
Apr 19, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02514382 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02514382: Wild-Type Reovirus, Bortezomi... | TrialScanner